Find information on thousands of medical conditions and prescription drugs.

Rh disease


Gastroesophageal reflux...
Rasmussen's encephalitis
Raynaud's phenomenon
Reactive arthritis
Reactive hypoglycemia
Reflex sympathetic...
Regional enteritis
Reiter's Syndrome
Renal agenesis
Renal artery stenosis
Renal calculi
Renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
Renal failure
Renal osteodystrophy
Renal tubular acidosis
Repetitive strain injury
Respiratory acidosis
Restless legs syndrome
Retinitis pigmentosa
Retrolental fibroplasia
Retroperitoneal fibrosis
Rett syndrome
Reye's syndrome
Rh disease
Rheumatic fever
Rheumatoid arthritis
Rift Valley fever
Rocky Mountain spotted fever
Romano-Ward syndrome
Roseola infantum
Rubinstein-Taybi syndrome
Rumination disorder

Rh disease (also Rhesus disease, Haemolytic Disease of the Newborn (HDNB) or Morbus haemolyticus neonatorum or erythroblastosis) is a condition that occurs when a Rh negative mother has given birth to a Rh positive baby and subsequently becomes pregnant with another Rh positive child. About 5% of at-risk pregnancies would result in still births or extremely sick babies. Many who managed to survive would be severely retarded. Once a woman gives birth to a baby with the disease, all subsequent babies would also have it. The connection between the Rh antigen and erythroblastosis was made in 1941 by Dr. Philip Levine. The treatment that came to be developed for the disease was blood transfusion, which was often ineffective or only partially ameliorative because the damage had already been done. Severely retarded children often resulted.

During the first pregnancy and the act of birth a small amount of the baby's blood may enter the mother's body. If the mother is Rh negative, her body produces antibodies (including IgG) against the Rhesus antigens on her baby's erythrocytes, if the baby is Rh positive. During the second pregnancy the IgG is able to pass through the placenta into the fetus, where it leads to agglutination and destruction of erythrocytes. The means to prevent this harmful disease is to vaccinate the mother immediately after the birth of her first child: she is treated with anti-Rh antibodies, so that the fetal erythrocytes are destroyed before her immune system can discover them.

This explanation of the etiology of the disease was first worked in 1960 out by Dr. Ronald Finn, a Liverpool, England native, who applied a microscopic technique for detecting fetal cells in the mother's blood. It lead him to propose that the disease might be prevented by injecting the at-risk mother with an antibody against fetal red blood cells. He proposed this for the first time to the public on February 18, 1960. A few months later, he proposed at a meeting of the British Genetical Society, that the antibody be anti-Rh. Nearly simultaneously with him, a group of researchers from New York City Columbia-Presbyterian Medical Center, John Gorman, Vince Freda, and Bill Pollack came to the same realization, and set out to prove it by injecting a group of male prisoners at Sing Sing Correctional Facility with anti-body supplied by Ortho Pharmaceutical Corporation. Dr. Gorman's daughter-in-law was the first at risk woman to receive a prophylactic injection on January 31, 1964. Clinical trials by the two rival groups, and others quickly confirmed their hypothesis, and the vaccine was finally approved in England and the United states in 1968. Within a year or so, it had been injected with great success into more than 500,000 women. Time magazine picked it as one of the top ten medical achievements of the 1960's. By 1973, it was estimated that in the US alone, over 50,000 baby's lives had been saved.


[List your site here Free!]

Computed Tomography in the Evaluation of Cystic Fibrosis Lung Disease
From American Journal of Respiratory and Critical Care Medicine, 11/15/05 by Brody, Alan S

The first report of computed tomography (CT) scanning to monitor cystic fibrosis (CF)-related lung disease was published in 1986. Further publications followed, but in general there was little interest in this technique until recently. Two factors in particular have led to this increased interest. First is an increasing realization that pulmonary function tests, long the mainstay of CF evaluation, often underestimate the presence and severity of mild and moderate lung disease. Second is the need for more sensitive outcome measures to assess new therapies. This had led to new interest and a series of important publications. The goal of this article is to present the current status of CT scanning in CF.

Keywords: computed tomography X-ray; cystic fibrosis; radiation effects; research design

The first report of computed tomography (CT) scanning to monitor cystic fibrosis (CF)-related lung disease was published in 1986 (1). Further publications followed, but in general there was little interest in this technique until recently. Two factors in particular have led to this increased interest. First is an increasing realization that the morphologic changes seen with CT scanning often precede the functional changes identified with pulmonary function tests (PFTs). Second is the need for more sensitive outcome measures to assess new therapies. In addition, new imaging techniques, including controlled ventilation and spirometric control of lung volume, have advanced the capabilities of CT scanning. These factors have led to new interest and a series of important publications. One result of these efforts has been a realization that CT scanning offers information that may be complementary to the information provided by PFTs, both in understanding the pathophysiology of CF lung disease and in evaluating patients. The goal of this article is to present the current status of CT scanning in CF.


The two CT techniques that have been used for the evaluation of CF lung disease are high-resolution CT (HRCT) and volumetric, or spiral, CT. Incremental HRCT uses thin sections (

The chief benefit of incremental HRCT scanning is an approximately eightfold decrease in radiation dose for the study compared with volumetric scanning, due primarily to the interval rather than complete exposure of the lung to the CT X-ray beam. Such surveys, if used as outcome measures, are suitable for qualitative evaluation using scoring systems but pose problems for (semi-)automated quantitative analysis and for longitudinal comparison. For example, in one study, each subject had only five to seven airway/vessel pairs large enough and sectioned near perpendicular to the long axis to allow accurate measurement (3). The average lumen diameter of the segmental airways in children between the ages of 0 and 5 yr measured by CT was 1 mm, which is near the limits of resolution (3). Using volumetric CT, the lungs can be rotated three-dimensionally, allowing more airways to be measured accurately anywhere along their course. Repeat volumetric scanning allows one to easily measure the same airway at the same location for longitudinal assessment. To obtain diagnostically useful images, the scan should be taken during a breath-hold at near full-inflation and end-exhalation volumes to eliminate motion artifacts, improve resolution, increase reproducibility, and optimize the detection of abnormalities. In young children, this can be done using the controlled ventilation technique for both inspiratory and expiratory images (4). In older children, inspiratory and expiratory images can be obtained by voluntary breath-holds at full inflation and deflation, or by spirometer-controlled scan acquisitions at defined full-inspiratory and -expiratory lung volumes (5).

When determining the number of images required for the evaluation of a specific lung disease, one should take the extent and distribution of the lung disease into account. On the basis of our preliminary experience, early CF lung disease may affect any lobe and is patchy in distribution, rather than evenly distributed through the lungs (6). A recent study has shown that incremental H RCT images at intervals greater than 10 mm will underestimate the severity of CF lung disease (7).

In summary, conventional HRCT techniques allow lower dose CT scanning and may be useful for qualitative evaluation. Volumetric CT is necessary for optimal longitudinal evaluation and for quantitative analysis.


For clinical management of CF-related lung disease to be effective, onset and progression of the lung disease should be closely monitored. This can be done either indirectly by monitoring lung function or more directly by monitoring lung structure. PFTs. such as spirometry and body plethysmography, are considered the most important tools for measuring lung function from the age of 5 or 6 yr and onwards. More recently, multiple-breath washout techniques were described as a promising alternative to detect early pulmonary changes (8, 9).

To monitor lung structure, chest radiographs have been used. Although quantitative chest radiograph scores have been shown to be higher at 2 yr of age than in infancy, the technique is described by the investigators as "complicated to use in nonstudy settings" (10). In adults, chest radiographs have been shown to be insensitive to acute changes, such as pulmonary exacerbations (11).

To monitor structural lung changes, it is current practice at the Columbus Children's Hospital to do a controlled-ventilation HRCT at diagnosis. In contrast to chest radiographs. CT scans often show abnormalities in young children with CF. In a study of 32 asymptomatic infants and toddlers with CF, 10 to 20% of airways measured were bronchiectatic and 20% had bronchial wall thickening (12). In addition, the airway lumen/vessel diameter ratio was increased relative to control subjects and was progressive with increasing age. To monitor lung structure at the Erasmus MC-Sophia, all patients with CF from the age of 4 yr have a thin-slice CT repeated every other year. To monitor lung function, dynamic flows and dynamic and static volumes (FEV^sub 1^, FVC. maximal expiratory flow at 25% of FVC [MEF^sub 25^], total lung capacity [TLC]. residual volume [RV]) are done routinely at the annual check-up. Figure 1 shows the dissociation between changes in lung function and lung structure in two patients who were part of a cohort study of 48 patients who were monitored for 2 yr (13). In the first patient, there were moderate structural abnormalities and mild lung function abnormalities initially. Two years later, structural abnormalities had markedly increased, although PFTs improved. Despite the improvement in pulmonary function, this patient has progressive damage to the lungs with increasing bronchiectasis and mucus plugging. On the basis of the CT findings, changes in treatment strategy, such as introduction of antiinflammatory treatment, more aggressive antibiotic treatment, and/or early introduction of recombinant human (rh)DNase, will be made. The second patient had marked structural abnormalities initially, indicated by the high CT score in the presence of only mildly abnormal PFTs. Two years later, the CT score was unchanged and PFTs had improved and were within the normal range. The CT findings indicate that there is definite lung damage despite normal PFTs. However, structural changes did not progress and lung function improved. It is likely that the treatment strategy for this patient will remain unchanged. This dissociation between structure and function was observed in many patients of the cohort study (Figure 2) (13). Other studies have also shown this dissociation. In children aged 6 to 10 yr, bronchiectasis was present in 30% of 37 children with normal PFTs (14). In a study of patients 12 yr to adult with an FEV^sub 1^ of greater than 90%, bronchiectasis was found in 73% (15).

These studies do not address the use of CT scanning for acute changes in patient status. Although CT scanning has been shown to reflect improvement in patients treated for respiratory tract exacerbations (16-18), no clinical advantage has been shown for this evaluation. The use of CT scanning has been suggested in the follow-up of patients with nontuberculous mycobacteria infection (19).

In summary, functional lung changes can be dissociated from structural changes. Thin-slice CT scanning is a more sensitive method than PFTs to detect structural changes and disease progression. Whether using CT in patient management improves the health of patients is not yet known.


To monitor CF lung disease in clinical trials as a primary endpoint. CT must be shown to provide a valid outcome surrogate. An outcome surrogate is a laboratory measurement or physical sign used as a substitute for a clinically meaningful endpoint. In CF, the only outcome surrogate currently accepted by the U.S. Food and Drug Administration is FEV^sub 1^. Outcome surrogates must meet strict criteria to ensure accurate results from clinical trials. One set of criteria was proposed by Robert Temple at the U.S. Food and Drug Administration (20). He wrote that a surrogate must be biologically plausible, reflect clinical severity, improve rapidly with effective therapy, and correlate with true outcomes. A recent review of imaging outcomes concluded that the presence of the surrogate should be closely linked to the presence of disease; detection of the surrogate must be accurate, reproducible, and feasible over time; and the changes must be closely linked to changes in the true endpoint (21).

Looking at CT scanning in terms of these criteria, we know that CT images are similar to pathologic specimens, and the criteria for bronchiectasis. for example, were developed from pathologic correlation studies (22). HRCT is a sensitive indicator of early CF lung disease and has provided evidence of bronchiectasis. peribronchial thickening, mosaic perfusion, and mucus plugging in infants and children with CF (23-25). HRCT differentiates CF lung disease from other conditions as shown by very rare identification of abnormalities typical of CF in normal subjects (3. 26). HRCT scores have been shown to correlate with other evaluations, including clinical status and PFTs, in multiple cross-sectional studies of persons with CF (16,17, 23-25, 27-32), indicating that higher CT scores are more common in subjects with worse PFTs despite the frequent dissociation of CT scores and PFTs in individual subjects and in longitudinal studies. A recent study by de Jong and coworkers (13) has shown that CT scores are reproducible. Studies have used HRCT to evaluate pulmonary disease progression in CF (27, 33). As part of a multicenter study to determine the effect of rhDNase on pulmonary function in subjects with CF aged 6 to 10 yr, serial HRCT scans were performed on 11 subjects over a 2-yr period. Visible peripheral bronchi were counted using a methodology used in children with difficult-to-treat asthma (34). Even though lung function remained stable over this 2-yr study, the number of visible airways on HRCT increased, suggesting that bronchiectasis worsened over this 2-yr period (unpublished data). Furthermore, findings from a 3-mo pilot study revealed improvements in HRCT subscores in young children with CF treated with rhDNase (18). Multiple studies have shown that CT scores improved after treatment of an exacerbation (16, 7, 32), indicating that CT scans improve after effective treatment. Recently, a 2-yr study was completed that showed that the change in CT score correlated with other outcome measures-in this case, respiratory tract exacerbations. In this study, there was no correlation between change in FEV^sub 1^ and the number of exacerbations (35).

CT scanning has the potential to detect disease sooner than FEV^sub 1^, allowing evaluation of therapies directed toward very early disease. In more advanced disease, CT scanning appears to be more sensitive to changes in lung disease than FEV^sub 1^ (27, 32), suggesting that if CT scanning becomes an accepted outcome surrogate, sample size and duration may be decreased when using CT as an outcome surrogate. Many of the recent CT data have come from long-duration trials without specific interventions. It will be necessary to demonstrate that CT reflects the effect of an effective intervention over a time course compatible with a therapeutic intervention trial to regard CT scanning as a valid outcome surrogate.


The data provided by a CT scan are a series of images. These graphic data must be converted to numeric data to be used in clinical trials, and to be most helpful in clinical care. This conversion is an essential component in the use of CT scanning in CF. Both expert reader systems and computer analysis programs have been used for this conversion.

Bhalla and colleagues (28) published the first HRCT scoring system for CF in 1991. Since then, several modifications have been published (17, 27, 30). In all systems, the reader identifies and assesses the severity of features associated with CF. Bronchiectasis, mucus plugging, airway wall thickening, and parenchymal opacities are included in all systems. Small nodules, mosaic attenuation, sacculations, and air trapping on expiratory images are included in some of the systems. The systems differ in how the severity of the features is assessed and, most strikingly, in how features are localized anatomically. Despite these differences, a comparison of five scoring systems-Castile and colleagues (12), Brody and colleagues (17), Helbich and coworkers (27) Santamaria and collleages (30), and Bhalla and coworkers (28)-showed similar results for each system (13). Twenty-five CT scans from children with CF aged 5 to 18 yr were scored and rescored after an interval of 1 to 2 wk and again after 1 to 2 mo by three observers. Between- and within-observer agreement was good with intraclass correlation coefficients generally greater than 0.8 (13). After this validation, the five systems were used in a 2-yr longitudinal study with 48 children with CF. There was no difference in the ability to track disease progression between the five scoring systems (32), likely reflecting the contribution of the features common to these different systems.

Another scoring system has been developed more recently (36). This system has been evaluated as part of the tracking of subjects in the Wisconsin Benefits of Neonatal CF Screening Project. This system was designed to provide lobar localization of findings and to independently assess each finding in each lobe. These scores could then be combined to provide an assessment of the total abnormality in each lobe, the extent of a specific finding in each patient, or the overall severity of CF lung disease. Evaluation of this system has shown ? coefficients with values greater than 0.4. indicating good agreement, in 74 of 96 subcomponents. The sensitivity, which was the square root of film-to-film variance, was quite good at 27.9. The reproducibility of the overall score was excellent at 98.1%. although individual lobe scores show a reproducibility that is around 40% or lower.

A composite CT/PFT score has also been proposed (37). In a 1-yr, double-blind, placebo-controlled study of rhDNase in children with CF, the largest difference in treatment effects measured by the change from baseline was the composite CT/PFT score which showed a 30% change compared with 13% for FEF^sub 25-75^ and 7% for the CT score alone.

For future studies, it will be important to develop a scoring system by consensus on the basis of previous studies and include features to be assessed using specific definitions.

This system should be able to show the severity of a specific feature at a specific anatomic location. A set of reference images would also reduce observer variation. This approach would also need to be tested (and validated) in different age groups and over a broad range of severity. The system would ideally be able to track progression of structural lung abnormalities from birth until end-stage lung disease.

Computer-based methods for quantifying the structure of the lung fall into two main areas: evaluation of the parenchyma and of the airway walls. Both of these approaches are important in CF where large airway wall abnormalities can be assessed by airway wall measurement, and small airway and parenchymal abnormalities can be assessed by changes in lung parenchymal attenuation or air trapping.

The accuracy of CT in the diagnosis and assessment of severity of parenchymal lesions, such as emphysema, has been well documented (38-42). Quantitative studies of lung CT have focused on the absorption of X-rays by the lung, and have related that to the volume of tissue and gas within the lung. It should be noted that lung density measurements on CT can be affected by a number of variables, including patient size, depth of inspiration, the type of CT scanner used, collimation, and the reconstruction algorithm.

The best-studied parameter using computerized analysis of CT scans in CF is air trapping. Air trapping is a finding present in early CF lung disease, which reflects small airway obstruction that can be indirectly measured with quantitative CT techniques. In a study comparing 25 subjects with mild CF with 10 normal subjects, only the RV/TLC was statistically different between groups for the PFTs (43). The quantitative air-trapping technique showed a far greater statistical difference between the groups (p = 0.0003). These subjects were then evaluated during a 1-yr intervention with rhDNase. No significant differences between groups were noted for any of the PFT measurements after 3 and 12 mo of treatment. There was a significant difference in quantitative air-trapping measurements between groups at 3 mo and a nearly significant difference between groups at 12 mo despite a smaller number of subjects (44).

The measurements of airway wall dimensions also have very important implications to the study of lung disease. Validation studies of airway measurements consistently show that there is a reasonable correlation between CT and pathologic measurements (45-48). The data suggest that accurate measurement requires sections 2 mm or less in thickness and is currently limited to airways 2 mm or more in diameter (45).

In summary, both scoring by expert observers and computer analysis has been used successfully to interpret CT scans in CF. Currently, expert observer scoring systems include more features of CF lung disease than can be evaluated by computer analysis. Computer analysis is an area of active investigation and new methods are likely to be developed, increasing the number of features that can be analyzed. Computer analysis does not require specially trained observers and could also be more sensitive to subtle changes, particularly in air trapping. Future studies should also further evaluate the use of an outcome measure that combines CT scanning and PFTs.


The best estimate of stochastic, or chance event, radiation risk, which includes the risk of developing cancer, is the patient-effective dose (49). Estimates from energy-imparted data (50, 51) or Monte Carlo simulations on mathematical phantoms (52-55) result in similar patient effective dose values of 0.25 to 0.50 millisieverts (mSv) for a 10- to 15-kg patient using a scanning technique expected to be as follows: 100 kV(p), 10 to 20 mA, pitch of 1.35, beam collimation of 8 × 1.25 mm or 16 × 1.25 mm; which reflects recent National Cancer Institute recommendations on reducing radiation dose to pediatric and small adult patients by using reduced kV(p), reduced mAs, and increased pitch values (56). The cumulative effective dose from one scan every other year from birth to age 30 with increasing X-ray techniques to reflect the increase in patient size would be approximately 10 to 15 mSv.

The effective dose from CT scanning can be compared with natural background. In the United States, cosmic radiation, natural radioactivity, and domestic radon result in an average exposure of approximately 3 mSv/yr. An average U.S. resident would thus expect to receive 90 mSv in their first 30 yr of life, or six times the radiation burden of the proposed 15 CT scans for patients with CF. Shielding in X-ray departments is designed to limit doses to the public to less than 1 mSv/yr, and to radiation workers to less than 50 mSv/yr. It is noteworthy that the dose limit to the embryo/fetus of a pregnant radiation worker is 5 mSv for the duration of the gestation period, with no more than 0.5 mSv received in any one month.

It is also possible to estimate the risk of fatal cancer to a small infant from a CT scan with an effective dose of 0.5 mSv. The International Commission on Radiological Protection (49) recommends using a nominal risk coefficient of 5% per sievert, which is increased threefold to account for the higher radiosensitivity of infants. The resultant risk is approximately one additional fatal cancer in 13,000. It is important to note that there is considerable uncertainty in this risk estimate, which is obtained by performing a linear extrapolation from known effects at high organ doses (> 0.1 Gy) to the much lower organ doses expected in these CT scans (~0.001 Gy).

Most CT protocols have been applied in a research setting, and it is unclear what benefit would accrue to patients from routine clinical examinations. Radiation risk needs to be weighed against the anticipated benefit to the patient from diagnostic CT scans.


Effective techniques are available to allow CT scanning to be performed in patients with CF of all ages. Quantitative and qualitative parameters derived from CT scans are more sensitive than currently used routine pulmonary function parameters to estimate structural lung changes in CF. Current studies suggest that CT scanning may require substantially fewer patients in clinical studies. Efforts to refine observational scoring systems and expand computerized scoring systems are in progress. Further studies showing that CT scanning is an effective outcome measure in intervention studies will be needed before CT scanning can be fully accepted as a valid outcome measure for CF lung disease.

Conflict of Interest Statement: A.S.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. H.A.W.M.T. has acted as consultant in research and development, in 2001 and 2002, as member of an advisory board on aerosolized antibiotics from Chiron Biopharmaceuticals, and received within the last 3 yr honoraria and travel expenses for lectures and workshops from Chiron, Hoffman-LaRoche, and Genentech, Inc., and holds no stock options. The BV Kindergeneeskunde of the Erasmus MC-Sophia has in the last 3 yr received research grants from Hoffman-LaRoche. R.G.C. will receive $161,836 between 2004 and 2006 from Genentech, Inc., as a research grant. H.O.C. received $2,500 in 2002 and £1,500 in 2003 for serving on an advisory board for GlaxoSmithKline (CSK). In addition, he is the coinvestigator on two multicenter studies sponsored by GSK and has received travel expenses to attend meetings related to the project. A percentage of his salary between 2003 and 2006 ($15,000/yr) derives from contract funds provided to a colleague, Peter D. Pare, by CSK for the development of validated methods to measure emphysema and airway disease using computed tomography. P.A.d.J. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.R.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.M.-G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. T.E.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.D.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Acknowledgment: Additional meeting attendees who participated in discussion included: Richard Ahrens, Andrew Bush, Stephanie Davis, Lynn Fordham, Michael Knowles, Ruth Milner, Robert Tepper, and Claire Wainwright.

The affiliations of the presenters as listed on the opening page, are: Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Department of Radiology, Cincinnati, OH (A.S.B.); Erasmus MC-Sophia, Rotterdam, Department of Pediatric Pulmonology, Rotterdam, The Netherlands (H.A.W.M.T. and P.A.d.J.); Vancouver General Hospital, Department of Radiology, Vancouver, British Columbia, Canada (H.O.C.); Columbus Children's Hospital, The Children's Radiological Institute, Columbus, OH, (R.G.C. and F.R.L.); David Geffen School of Medicine at University of California Los Angeles, Department of Radiology, Los Angeles, CA (J.G. and M.M.-G.); State University of New York Upstate Medical University, Syracuse, NY (W.H.); University of Wisconsin, Madison, WI (M.R.); Packard Children's Hospital at Stanford, Division of Pediatric Pulmonology, Palo Alto, CA (T.E.R.); Children's Hospital of Denver, Denver, CO (S.D.S.)


1. Jacobsen LE, Houston CS, Habbick BF, Genereux GP, Howie JL. Cystic fibrosis: a comparison of computed tomography and plain chest radiographs. Can Assoc Radial J 1986;37:17-21.

2. Mayo JR, Jackson SA, Muller NL. High-resolution CT of the chest: radiation dose. AJR Am J Roentgenol 1993;160:479-481.

3. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-161.

4. Long FR, Castile RG, Brody AS, Hogan MJ, Flucke RL, Filbrun DA, McCoy KS. Lungs in infants and young children: improved thin-section CT with a noninvasive controlled-venlilalion technique-initial experience. Radiology 1999;212:588-593.

5. Robinson TE, Leung AN, Moss RB. Blankenberg FG, al-Dabbagh H, Northway WH. Standardized high-resolution CT of the lung using a spirometer-triggered electron beam CT scanner. AJR Am J Roentgenol 1999;172:1636-1638.

6. Helbich TH, Heinz-Peer G Eichler I, Wunderbaldinger P, Gotz M, Wojnarowski C, Brasch RC, Herold CJ. Cystic fibrosis: CT assessment of lung involvement in children and adults. Radiology 1999;213:537-544.

7. de Jong PA, Golmohammadi K, Nakano Y, Mayo JR, Lequin MH, Tiddens HA, Aldrich J, Pare PD, Sin DD. Risks, benefits and risk reduction of repetitive computed tomograph (CT) scanning in cystic fibrosis. J Cyst Fibros 2005;4:563.

8. Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J, Stroobant J, Carr S, Stocks J. Multiple-breath washout as a marker of lung disease in preschool children with cystic librosis. Am J Respir Crit Care Med 2005;171:249-256.

9. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003;22:972-979.

10. Farrell PM, Li Z. Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003;36:230-240.

11. Greene KE, Takasugi JE, Godwin JD, Richardson ML, Burke W, Aitken ML. Radiographic changes in acute exacerbations of cystic fibrosis in adults: a pilot study. AJR Am J Roentgenol 1994;163:557-562.

12. Castile R, Long F, Flucke R, Goldstein A, Filbrun D, Brody A, McCoy KS. High resolution computed tomography of the chest in infants with cystic fibrosis. Pediatr Pulmonol 1999;28(S19):277-278.

13. de Jong PA, Ottink MD, Robben SG, Lequin MH, Hop WC, Hendriks JJ, Pare PD, Tiddens HA. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004;231:434-439.

14. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145:32-38.

15. Brody A, Campbell J, Millard S, Moss RB, Heald AE. Relationship between FEVl and high resolution chest CT findings in CF patients with mild lung disease: baseline data from the AAV2 phase II gene transfer study. Pediatr Pulmonol 2003;36(S25):319.

16. Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997;169:375-380.

17. Brody AS, Molina PL, Klein JS, Rothman BS, Ramagopal M, Swartz DR. High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999;29:731-735.

18. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Moss RB. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. J Pediatr 2001;138:553-559.

19. Maiz-Carro L, Navas-Elorza E. Nontuberculous mycobacterial pulmonary infection in patients with cystic fibrosis: diagnosis and treatment. Am J Respir Med 2002;1:107-117.

20. Temple RJ. A regulator authority's opinion about surrogate endpoints. In: Nimmo WS, editor. Clinical measurements on drug evaluation. New York: Wiley; 1995.

21. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging: realizing radiology's future. Radiology 2003;227:633-638.

22. Kang EY, Miller RR, Muller NL. Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology 1995;195:649-654.

23. Stiglbauer R, Schurawitzki H, Eichler I, Vergesslich KA, Gotz M. High resolution CT in children with cystic fibrosis. Acta Radiol 1992;33:548-553.

24. Maffessanti M, Candusso M, Brizzi F, Piovesana F. Cystic fibrosis in children: HRCT findings and distribution of disease. J Thorac Imaging 1996;11:27-38.

25. Marchant JM, Masel JP, Dickinson FL, Masters IB, Chang AB. Application of chest high-resolution computer tomography in young children with cystic fibrosis. Pediatr Pulmonol 2001;31:24-29.

26. Lynch DA, Brasch RC, Hardy KA, Webb WR. Pediatric pulmonary disease: assessment with high-resolution ultrafast CT. Radiology 1990; 176:243-248.

27. Helbich TH, Heinz-Peer G, Fleischmann D, Wojnarowski C, Wunderbaldinger P, Huber S, Eichler I, Herold CJ. Evolution of CT findings in patients with cystic fibrosis. AJR Am J Roentgenol 1999;173:81-88.

28. Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, Naidich DP. Cystic fihrosis: scoring system with thin-section CT. Radiology 1991;179:783-788.

29. Nathanson I, Conhoy K, Murphy S, Afshani E, Kuhn JP. Ultrafast computerized tomography of the chest in cystic fibrosis: a new scoring system. Pediatr Pulmonol 1991;11:81-86.

30. Santamaria F, Grillo G, Guidi G, Rotondo A, Raia V, de Ritis G, Sarnelli P, Caterino M, Greco L. Cystic fibrosis: when should high-resolution computed tomography of the chest be obtained? Pediatrics 1998;101: 908-913.

31. Demirkazik FB, Ariyurek OM, Ozcelik U, Gocmen A, Hassanabad HK, Kiper N. High resolution CT in children with cystic fibrosis: correlation with pulmonary functions and radiographic scores. Eur J Radiat 2001; 37:54-59.

32. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Pare PD, Tiddens HA. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23:93-97.

33. Marchac V. Emond S, Mamou-Mani T, Le Bihan-Benjamin C, le Bourgeosis M, de Blic J, Scheinmann P, Brunelle F. Thoracic CT in pediatric patients with difficult-to-treat asthma. AJR Am J Roentgenol 2002; 179:1245-1252.

34. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001;31:377-382.

35. Brody A, Klein J, Molina P, Campbell J, Millard S, Quan J. HighResolution CT correlates with the number of exacerbations in young children with CF. Pediatric Pulmonol 2003;36(S25):318-319.

36. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B. et al. Repeated adenoassociated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125: 509-521.

37. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;168:588-593.

38. Hayhurst MD, MacNee W, Flenley DC, Wright D, McLean A, Lamb D. Wightman AJ, Best J. Diagnosis of pulmonary emphysema by computerised tomography. Lancet 1984;2:320-322.

39. Muller NL, Staples CA, Miller RR, Abboud RT. "Density mask": an objective method to quantitate emphysema using computed tomography. Chest 1988;94:782-787.

40. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1995;152:653-657.

41. Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, Yernault JC. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996;154:187-192.

42. Coxson HO, Rogers RM, Whittall KP, D'Yachkova Y, Pare PD, Sciurba FC, Hogg JC. A quantification of the lung surface area in emphysema using computed tomography. Am J Respir Crit Cure Med 1999;159: 851-856.

43. Goris ML, Zhu HJ, Blankenberg F, Chan F, Robinson TE. An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Chest 2003;123:1655-1663.

44. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;168:588-593.

45. Nakano Y, Muller NL, King GG, Niimi A, Kalloger SE, Mishima M, Pare PD. Quantitative assessment of airway remodeling using highresolution CT. Chest 2002;222:271S-275S.

46. McNitt-Gray MF, Goldin JG, Johnson TD, Tashkin DP, Aberle DR. Development and testing of image-processing methods for the quantitative assessment of airway hyperresponsiveness from high-resolution CT images. J Comput Assist Tomogr 1997;21:939-947.

47. King GG, Muller NL, Whittall KP, Xiang QS, Pare PD. An analysis algorithm for measuring airway lumen and wall areas from high-resolution computed tomographic data. Am J Respir Crit Care Med 2000;161: 574-580.

48. Reinhardt JM, D'Souza ND, Hoffman EA. Accurate measurement of intrathoracic airways. IEEE Trans Med Imaging 1997;16:820-827.

49. International Council on Radiation Protection. Risks associated with ionizing radiations. Publication 60. Oxford, UK: Elsevier: 1991.

50. Huda W, Atherton JV, Ware DE, Cumming WA. An approach for the estimation of effective radiation dose at CT in pediatric patients. Radiology 1997;203:417-422.

51. Huda W, Scalzetti EM, Roskopf M. Effective doses to patients undergoing thoracic computed tomography examinations. Med Phys 2000;27: 838-844.

52. Jones DG, Shrimpton PC. Survey of CT practice in the UK. Part 3: normalised organ doses calculated using Monte Carlo techniques. Chilton, Oxon, UK: National Radiological Protection Board; 1992. NRPB R-250.

53. Jones DG, Shrimpton PC. Normalised organ doses for X-ray computed tomography calculated using Monte Carlo techniques. Computer software report. Chilton, Oxon, UK: National Radiological Protection Board; 1992. NRPB SR-250.

54. Shrimpton PC, Jones DG. Normalised organ doses for X-ray computed tomography calculated using the Monte Carlo techniques and a mathematical anthropomorphic phantom. Radiat Prot Dosimetry 1993;49:241-243.

55. Khursheed A, Hillier MC, Shrimpton PC, Wall BF. Influence of patient age on normalized effective doses calculated for CT examinations. Br J Radiol 2002;75:819-830.

56. Feigal D. FDA public health notification: reducing radiation risk from computed tomography for pediatric and small adult patients. Rockville, MD: Center for Devices and Radiological Health, Food and Drug Administration. Available from: (accessed November 2001).

Alan S. Brody, Harm A. W. M. Tiddens, Robert G. Castile, Harvey O. Coxson, Pim A. de Jong, Jonathan Goldin, Walter Huda, Frederick R. Long, Michael McNitt-Gray, Michael Rock, Terry E. Robinson, and Scott D. Sagel for the CT Scanning in Cystic Fibrosis Special Interest Group

Department of Radiology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati; Columbus Children's Hospital, The Children's Radiological Institute, Columbus, Ohio; Department of Pediatric Pulmonology, Erasmus MC-Sophia, Rotterdam, The Netherlands; Department of Radiology, Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Radiology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles; Division of Pediatric Pulmonology, Packard Children's Hospital at Stanford, Palo Alto, California; State University of New York Upstate Medical University, Syracuse, New York; University of Wisconsin, Madison, Wisconsin; and Children's Hospital of Denver, Denver, Colorado

(Received in original form March 19, 2005; accepted in final form August 9, 2005)

This conference was supported by the Cystic Fibrosis Foundation.

Alan Brody and Harm Tiddens jointly organized and chaired the CT scanning in Cystic Fibrosis Special Interest Group meeting held October 17, 2003, in Anaheim, California, sponsored by the North American Cystic Fibrosis Foundation. This report, jointly written by Alan Brody and Harm Tiddens, summarizes the presentations by those listed above. See ACKNOWLEDGMENTS at end of article for additional information.

Correspondence and requests for reprints should be addressed to Alan S. Brody, M.D., Professor of Radiology and Pediatrics, Department of Radiology, MLC-5031, Cincinnati Children's Hospital, 3333 Burnet Avenue, Cincinnati, OH 45229-3039. E-mail:

Am J Respir Crit Care Med Vol 172. pp 1246-1252, 2005

Originally Published in Press as DOI: 10.1164/rccm.200503 401PP on August 11, 2005

Internet address:

Copyright American Thoracic Society Nov 15, 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Rh disease
Home Contact Resources Exchange Links ebay